So a "generic" version of insulin would be something called a biosimilar ... The one CVS Health opted to cover in 2017, Basaglar (though technically considered a "follow on," not a biosimilar ...

Basaglar is a long-acting insulin that may be available through Medicare Part D. If a person’s drug plan includes Basaglar, the plan cannot charge more than $35 per month. Basaglar is a brand ...

Basaglar has been approved as a "follow-on" drug based on clinical comparisons ... undercutting the long-acting Levemir (insulin detemir) by 21% and Tresiba (insulin degludec) an ultra long ...

The Basaglar NDA was filed through the FDA's 505(b)(2) regulatory pathway, which allows the agency to consider the efficacy and safety of the existing insulin glargine product. The drug was ...